Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Documents similaires

• Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality
  par: Donghee Kim, et autres
  Publié: (2024)
• Vitamin E improves serum markers and histology in adults with metabolic dysfunction‐associated steatotic liver disease: Systematic review and meta‐analysis
  par: Nicholas Ming‐Zher Chee, et autres
  Publié: (2024)
• Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians
  par: Tingfeng Wu, et autres
  Publié: (2024)
• Deciphering metabolic dysfunction‐associated steatotic liver disease: insights from predictive modeling and clustering analysis
  par: Kazuma Mori, et autres
  Publié: (2024)
• Lower hepatocellular carcinoma surveillance in metabolic dysfunction‐associated steatotic liver disease: Impact on treatment eligibility
  par: Connor Henry‐Blake, et autres
  Publié: (2024)